NextFin News - Oura postponed its initial public offering on Tuesday, pulling the up-to-$2.2 billion smart-ring listing off the calendar after some investors in the deal pushed back against a valuation that would have reached $15.62 billion, a blow to hopes for a revival of the fall IPO window. The company said it was delaying "despite strong demand, due to uncertainty in the IPO market," a formulation that papers over a sharper reality: after a year of private-market repricing elsewhere, the public market was refusing to pay the price.
The delay, confirmed by the San Francisco-based company on September 29, comes just over a week after Oura launched its roadshow on September 21 seeking to sell 50 million shares at $40 to $44 apiece, with trading on the Nasdaq under the ticker OURA expected as soon as the week of September 28. The postponement marks the latest retreat by a high-profile issuer in a September that has been sluggish for new listings, and it raises a question that extends well beyond one wearable company: after years of cheap capital, can the public market still absorb private valuations set at the peak of the low-rate era?
The Deal That Would Not Price
Oura's IPO terms, disclosed in a filing that became public on September 3, were aggressive by any measure. The company and some existing investors planned to raise as much as $2.2 billion at the top of the indicated range, which would have handed the company a fully-diluted valuation of $15.62 billion. Even at the midpoint of the $40-to-$44 range, the deal would have valued Oura at roughly $15 billion, according to the roadshow materials.
That price tag represented a steep climb from the company's last private mark. In October 2025, Oura raised $900 million in a Series E round at an $11 billion valuation, bringing total capital raised to more than $1.5 billion. The IPO range therefore implied roughly a 36 percent uplift on the private round in less than a year — a jump the public market was being asked to underwrite while interest rates, inflation expectations, and appetite for consumer technology were all shifting at once.
The structure of the offering itself signaled the pressure. Of the 50 million shares on offer, only 13.5 million were primary shares sold by the company; the remaining 36.5 million, about 73 percent of the deal, were secondary shares sold by existing holders. Underwriters Goldman Sachs, Morgan Stanley, and J.P. Morgan were therefore marketing a transaction in which nearly three-quarters of the proceeds would flow to early investors cashing out, not to the company's balance sheet. When a large secondary overhang meets a skeptical book, the price is the first thing to break.
The valuation math is unforgiving. Oura reported revenue of $1.21 billion for the nine months ended June 30, up 74 percent from $697.6 million in the prior-year period, and disclosed shipments of 3.1 million rings during that stretch. For the full fiscal year 2025, revenue grew 123 percent to $907.9 million from $406.8 million in 2024. At $16 billion, the company was pricing at roughly 18 times trailing sales — a multiple that would have ranked it among the most expensive consumer-hardware listings in years, and one that assumed growth would continue at a pace the public markets have recently punished rather than rewarded.
The profitability story, while real, was not enough to bridge the gap. Oura posted net income of $60.77 million in the first nine months of fiscal 2026, up from $1.57 million a year earlier, on adjusted EBITDA of about $107 million. But for full-year 2025, net income was essentially breakeven at $12,000. The company is profitable on a trailing basis, yet the earnings base is too thin to justify a hardware multiple, and the revenue base is still too hardware-heavy to justify a software multiple.
According to people with knowledge of the matter, some investors in the offering pushed back on the valuation during the roadshow, arguing that the price did not leave enough room for the risks embedded in a single-product hardware business. The company's response, delivered through CEO Tom Hale, was to walk away rather than cut the price.
"Our mission is to empower people to live healthier, longer, and an IPO is just one step in our journey," Hale said in a prepared statement. "We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment. In the meantime, we will execute against the opportunities ahead."
The phrase "the luxury of choosing our moment" is doing heavy lifting. It signals that Oura's private balance sheet — swollen by more than $1.5 billion in raised capital and a newly profitable core — gives it the option value to wait. But it also concedes that the price on offer was not the price the market would clear.
Why the Public Market Said No
The rejection of Oura's terms is not an isolated event; it is the latest data point in a widening gap between private and public market pricing for growth technology. Three forces converged to make the $15.62 billion ask untenable.
First, the macro backdrop for IPOs deteriorated sharply during the roadshow itself. The offering launched against a market on edge over uncertainty around the AI trade, rising bond yields, and a shifting Federal Reserve rate outlook. Higher yields raise the discount rate applied to future earnings, which hits long-duration growth stocks hardest — and a company pricing at 18 times sales is, by definition, selling cash flows that sit far in the future. A 100-basis-point move in the discount rate can compress such a multiple by a third without a single dollar of fundamentals changing.
Second, the revenue mix works against a clean narrative. Oura charges $399 to $499 for a ring, then $5.99 a month to unlock most of the device's data and health insights. In the first nine months of fiscal 2026, hardware contributed $974 million, or 80 percent of revenue, while membership subscriptions contributed $240.5 million, or 20 percent. That subscription layer is the company's argument for a software-like multiple — membership revenue grew 121 percent year over year in the period and carries an 89 percent gross margin that rivals pure software companies. But the blended gross margin sits at 55 percent, and 80 percent of the top line still depends on convincing consumers to buy a piece of jewelry. Investors who balked at the valuation were, in effect, refusing to pay a software multiple for a business whose cash generation still runs through a hardware box.
Third, the comparables have turned hostile. The broader wearables category is crowded with well-capitalized incumbents: Apple continues to add health features to the Apple Watch, Google announced a new screenless Fitbit, and Garmin reported a 42 percent increase in fitness-product revenue in the first quarter of 2026 on "strong demand for advanced wearables." Even Oura's closest private peer, Whoop, raised $575 million in March at a $10.1 billion valuation — nearly $5 billion below where Oura was asking the public market to put it. When the nearest private comparable trades at a discount to your IPO ask, the ask is the problem.
The timing also matters. Oura was widely framed as the first real test of U.S. investor appetite after a tepid start to the fall IPO season. "If it comes strongly out the gate, it will encourage other issuers," said Samuel Kerr, global head of equity capital markets at Mergermarket, earlier in the roadshow. Instead, it has become a cautionary tale for the pipeline that follows.
The Cyclical Read: This Is a Window Problem, Not a Company Problem
The strongest case for Oura is that this delay is cyclical, not fundamental — a function of a closed IPO window rather than a broken business. The company's growth is genuine and hard to dispute. Paid members doubled from 2024 to 2025 and again in 2026, reaching 5 million as of June 30, spread across 56 markets. The company expects roughly 5.7 million paid members by the end of fiscal 2026, a 96 percent increase over the prior year. Revenue grew 74 percent year over year in the first nine months of fiscal 2026, and the company is now profitable at the corporate level. A consumer brand that is both growing at that pace and generating positive net income is rare in any market.
The historical precedent supports the cyclical view. IPO windows open and close on liquidity and sentiment, not on the quality of individual issuers. Companies that postponed in 2022 and 2023 — when the IPO market effectively froze after the 2021 boom — returned to public listings in 2024 and 2025 at equal or better valuations once rates stabilized and demand returned. Oura's own funding history illustrates the pattern in miniature: it hit a $5 billion valuation in an earlier round during the digital-health reset, then jumped to $11 billion once growth reaccelerated. Private marks move in waves; public markets will, too.
Under this reading, Hale's "the luxury of choosing our moment" is not bravado but rational option exercise. With more than $1.5 billion raised and a profitable core, Oura can afford to wait for a quarter with lower yields, calmer equity volatility, and a warmer reception for consumer technology. The delay costs the company nothing it cannot afford, while repricing now would set a weak anchor for every future financing.
There is also evidence that the market is not rejecting growth outright. SK hynix's $26.5 billion technology offering priced in July and rose 12.8 percent on its first day. The window has not closed; it has narrowed to issuers with the right price. Oura can still be one of them — later.
The Structural Read: The Multiple May Never Come Back
The counter-thesis is that the multiple Oura sought was itself the artifact of a regime that is not returning, and that waiting simply defers an inevitable haircut. This is the argument investors who pushed back were making, and it deserves weight.
The low-rate era taught a generation of private companies to model exit valuations on multiples that assumed near-zero discount rates and unlimited growth capital. Those conditions have structurally changed. If the neutral rate has moved higher for reasons of fiscal deficits, deglobalization, and capital scarcity — rather than as a temporary inflation overshoot — then a 15-to-18 times sales multiple for a hardware-led consumer brand is not a cyclical low-water mark; it is a valuation that the public market will not revisit until growth proves durable across multiple rate cycles.
There is also a company-specific structural risk that no amount of timing can fix: concentration. Oura is, at its core, a single product. The subscription attach rate and the $5.99 monthly fee are the growth story, but the installed base depends on continuous hardware refreshes in a category where consumers already own a watch, a band, or a phone that tracks many of the same metrics. The company says about 30 percent of new members are replacing an existing wearable — which means 70 percent are incremental, but it also means the replacement cycle is the moat, and moats built on upgrade cadence are thinner than moats built on switching costs.
A class-action lawsuit alleging the company misled users about the quality of its sleep tracking — which Oura disputes — underscores the fragility of a brand built on measurement accuracy. If the data is questioned, the subscription is questioned, and the multiple collapses with it.
Kat Liu, vice president at IPOX, captured the tension earlier in the roadshow: "One of Oura's strengths is that it is beginner friendly, fashionable and feels more like an easy add-on to everyday life, compared with some wearables that are more geared toward serious athletes and performance tracking." That is a real strength — and it is also a description of a discretionary lifestyle purchase, the first thing consumers cut when budgets tighten.
The adversarial answer, then, is this: the cyclical view wins if the neutral rate proves temporary and Oura's subscription revenue compounds fast enough to reframe the company as software. The structural view wins if hardware refresh cycles stall or if the subscription attach rate plateaus below what the $15 billion multiple assumes. The two are not reconcilable; one of them is an expensive mistake.
What Comes Next for the IPO Window
The immediate consequence of Oura's delay is a chill on the rest of the fall pipeline. Other large issuers were watching this deal as a bellwether; a failed test makes them more likely to wait, which thins the pipeline further and reinforces the very uncertainty that caused the delay. A quarterly review of U.S. IPO activity noted that several sizable deals postponed before pricing, including Holtec Nuclear's $825 million offering amid a struggling nuclear sector and Bamboo Insurance's $665 million deal after insurance peer Orion180 performed poorly in its debut. Postponements beget postponements.
The underwriters — Goldman Sachs, Morgan Stanley, and J.P. Morgan — now face a choice: bring Oura back at a lower price, or wait for conditions to improve. History suggests the second path is more likely for an issuer with Oura's private-market backing. But every month of waiting increases the pressure from investors who funded the $11 billion round and are now watching the public exit door close.
For the broader market, the signal is clear: the public market is no longer a passive buyer of private valuations. Issuers that priced their private rounds on low-rate-era assumptions will either accept a repricing in spirit, if not in name, or stay private longer. The IPO window has not closed — SK hynix's $26.5 billion technology offering in July priced and rose 12.8 percent on its first day — but it has narrowed to deals where the price is right, not just the story.
What to Watch
Three signals will determine whether Oura's delay is a pause or a verdict. First, the 10-year Treasury yield: a sustained move back below recent highs would reopen the window for long-duration growth issuers within a quarter. Second, Oura's next private financing: if the company raises more capital at a flat or down valuation, the $11 billion private mark — let alone $15.62 billion — is no longer supportable. Third, the subscription metrics: paid-member growth above the projected 96 percent pace, membership revenue holding its 121 percent growth rate, and an expanding attach rate would validate the software-multiple argument and make a future IPO at a strong price far more likely.
The falsifying signal: if Oura returns to market within six months at a valuation at or above $15 billion and prices successfully, the structural-repricing thesis is wrong and this was purely a timing problem. If it instead raises privately below $11 billion, the haircut has already happened — just without a ticker.
Short term, the signal is negative for the fall IPO pipeline: other issuers watching Oura as a bellwether are more likely to wait, and waiting thins the pipeline further, reinforcing the uncertainty that caused the delay in the first place.
Medium term, the base case is a delay of several quarters, with Oura returning once yields stabilize and the IPO pipeline thickens. The upside case is a rapid reopening of the consumer-technology window, allowing the company to relist near its original terms. The downside case is a prolonged private-market repricing that forces a down round before any public listing.
Long term, the verdict turns on whether the subscription layer can outrun the hardware cycle. If membership revenue keeps compounding at triple-digit rates and the installed base refreshes on a reliable cadence, Oura graduates into a software-multiple business and this delay becomes a footnote. If not, the $15.62 billion number was not a moment in a cycle — it was the top.
Oura did not fail because the business broke; it failed to price because the market changed. The company that walks away from a bad IPO today may look prescient in two years — or it may look like the last holder of a multiple that the public market decided, quietly and finally, it would no longer pay.
Explore more exclusive insights at nextfin.ai.
